S&P 500   3,985.37 (+0.86%)
DOW   32,419.72 (+0.54%)
QQQ   308.50 (+0.83%)
AAPL   158.61 (+0.77%)
MSFT   271.64 (-0.22%)
META   200.66 (+1.44%)
GOOGL   104.74 (+3.48%)
AMZN   99.59 (+1.92%)
TSLA   196.04 (+6.98%)
NVDA   260.45 (+0.56%)
NIO   9.26 (+5.83%)
BABA   83.38 (+2.94%)
AMD   95.45 (-1.40%)
T   18.50 (+0.05%)
F   11.76 (+5.19%)
MU   58.42 (+1.35%)
CGC   1.98 (+6.45%)
GE   92.61 (+2.99%)
DIS   96.29 (+2.20%)
AMC   4.41 (+3.28%)
PFE   40.42 (-0.96%)
PYPL   75.84 (+3.59%)
NFLX   305.61 (+0.16%)
S&P 500   3,985.37 (+0.86%)
DOW   32,419.72 (+0.54%)
QQQ   308.50 (+0.83%)
AAPL   158.61 (+0.77%)
MSFT   271.64 (-0.22%)
META   200.66 (+1.44%)
GOOGL   104.74 (+3.48%)
AMZN   99.59 (+1.92%)
TSLA   196.04 (+6.98%)
NVDA   260.45 (+0.56%)
NIO   9.26 (+5.83%)
BABA   83.38 (+2.94%)
AMD   95.45 (-1.40%)
T   18.50 (+0.05%)
F   11.76 (+5.19%)
MU   58.42 (+1.35%)
CGC   1.98 (+6.45%)
GE   92.61 (+2.99%)
DIS   96.29 (+2.20%)
AMC   4.41 (+3.28%)
PFE   40.42 (-0.96%)
PYPL   75.84 (+3.59%)
NFLX   305.61 (+0.16%)
S&P 500   3,985.37 (+0.86%)
DOW   32,419.72 (+0.54%)
QQQ   308.50 (+0.83%)
AAPL   158.61 (+0.77%)
MSFT   271.64 (-0.22%)
META   200.66 (+1.44%)
GOOGL   104.74 (+3.48%)
AMZN   99.59 (+1.92%)
TSLA   196.04 (+6.98%)
NVDA   260.45 (+0.56%)
NIO   9.26 (+5.83%)
BABA   83.38 (+2.94%)
AMD   95.45 (-1.40%)
T   18.50 (+0.05%)
F   11.76 (+5.19%)
MU   58.42 (+1.35%)
CGC   1.98 (+6.45%)
GE   92.61 (+2.99%)
DIS   96.29 (+2.20%)
AMC   4.41 (+3.28%)
PFE   40.42 (-0.96%)
PYPL   75.84 (+3.59%)
NFLX   305.61 (+0.16%)
S&P 500   3,985.37 (+0.86%)
DOW   32,419.72 (+0.54%)
QQQ   308.50 (+0.83%)
AAPL   158.61 (+0.77%)
MSFT   271.64 (-0.22%)
META   200.66 (+1.44%)
GOOGL   104.74 (+3.48%)
AMZN   99.59 (+1.92%)
TSLA   196.04 (+6.98%)
NVDA   260.45 (+0.56%)
NIO   9.26 (+5.83%)
BABA   83.38 (+2.94%)
AMD   95.45 (-1.40%)
T   18.50 (+0.05%)
F   11.76 (+5.19%)
MU   58.42 (+1.35%)
CGC   1.98 (+6.45%)
GE   92.61 (+2.99%)
DIS   96.29 (+2.20%)
AMC   4.41 (+3.28%)
PFE   40.42 (-0.96%)
PYPL   75.84 (+3.59%)
NFLX   305.61 (+0.16%)
CVE:LBL

Lattice Biologics - LBL Stock Forecast, Price & News

C$0.04
0.00 (0.00%)
(As of 06/3/2021)
Add
Compare
Today's Range
C$0.04
▼
C$0.04
50-Day Range
C$0.04
▼
C$0.04
52-Week Range
C$0.03
▼
C$0.13
Volume
114,000 shs
Average Volume
468,022 shs
Market Capitalization
C$5.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Lattice Biologics

Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologic products for use in the field of bone regeneration in dental, spine, and general orthopedic indications worldwide. It develops novel amniotic fluid-based products, such as AmnioBoost and AmnioBlast. The company also offers traditional, spinal, particulate, soft tissue, dental, membrane and barrier, and demineralized bone matrix allografts. Its products are used in a range of applications, including enhancing fusion in spine surgery and breast reconstruction post mastectomy, promotion of bone regeneration in foot and ankle surgery, promotion of skull healing following neurosurgery, enhancing wound repair in burn victims, hernia repair, and subchondral bone defect repair in knee and other joint surgeries, as well as sports medicine indications, such as anterior and posterior cruciate ligament repair. The company is headquartered in Belgrade, Montana.

Receive LBL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lattice Biologics and its competitors with MarketBeat's FREE daily newsletter.

LBL Stock News Headlines

March 2, 2023 | investing.com
Lattice Biologics Ltd (LBLh)
September 23, 2022 | markets.businessinsider.com
Lattice Announces Lattice Connect Partner Ecosystem to Help Organizations Maximize People Success
March 21, 2023 | Press Research (Ad)
Stocks For Smart Investors
This under-the-radar stock is in the right industry at the perfect time.
September 9, 2022 | morningstar.com
Lattice Semiconductor Corp LSCC Stock Quote
October 26, 2021 | finance.yahoo.com
Notice of Lattice Biologics Ltd. Year End 2016 Financial Results Conference Call
June 9, 2021 | ca.finance.yahoo.com
IIROC Trading Halt - LBL
March 31, 2021 | finance.yahoo.com
Lattice Announces Strategic Advisory Board
March 19, 2021 | finance.yahoo.com
Lattice Announces Strategic Cannabis Supply Agreement With Firehouse
March 21, 2023 | Press Research (Ad)
Stocks For Smart Investors
This under-the-radar stock is in the right industry at the perfect time.
March 15, 2021 | finance.yahoo.com
Lattice Biologics Reorganizes to Focus on Psychedelics and Cannabis Therapies
March 3, 2021 | uk.finance.yahoo.com
Lattice Biologics Ltd. Announces Resignation of Director
December 14, 2020 | marketwatch.com
Depth Filtration Market Research By Key Players, Type And Application, Future Growth To 2026
December 2, 2020 | markets.businessinsider.com
News for Lattice Biologics Ltd
August 31, 2020 | businesswire.com
Lattice Biologics Ltd. Reports Q3 2020 Results
August 14, 2020 | finance.yahoo.com
Lattice Biologics Ltd. (LBLTF)
July 23, 2020 | finance.yahoo.com
What Did Lattice Biologics' (CVE:LBL) CEO Take Home Last Year?
June 2, 2020 | www.businesswire.com
190,524
May 11, 2020 | www.businesswire.com
Lattice Biologics Update
April 15, 2020 | www.baystreet.ca
Health-Related Concerns Have Exciting, Stock-Moving News
April 15, 2020 | finance.yahoo.com
Lattice Biologics Ltd. Announces Option Repricing
March 11, 2020 | finance.yahoo.com
Lattice Biologics Announces Planned Debt-to-Equity Conversion
March 3, 2020 | finance.yahoo.com
LATTICE BIOLOGICS LTD. Transferred To TSX Venture Exchange Tier 2
February 28, 2020 | www.businesswire.com
Lattice Biologics Ltd. Reports Q1 2020 Results
November 19, 2019 | finance.yahoo.com
Did Changing Sentiment Drive Lattice Biologics's (CVE:LBL) Share Price Down A Painful 90%?
August 21, 2019 | finance.yahoo.com
What Kind Of Share Price Volatility Should You Expect For Lattice Biologics Ltd. (CVE:LBL)?
May 31, 2019 | www.businesswire.com
Lattice Biologics Ltd. Reports Second Quarter 2019 Results
May 24, 2019 | ca.finance.yahoo.com
Did Changing Sentiment Drive Lattice Biologics's (CVE:LBL) Share Price Down A Painful 85%?
See More Headlines
Receive LBL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lattice Biologics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
CVE
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
CVE:LBL
CUSIP
N/A
CIK
N/A
Web
www.latticebiologics.com
Phone
+1-604-2356701
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.02
Quick Ratio
0.02

Sales & Book Value

Annual Sales
C$1.56 million
Price / Sales
3.29
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
C$0.00 per share
Price / Book
40.00

Miscellaneous

Outstanding Shares
128,218,000
Free Float
N/A
Market Cap
C$5.13 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Guy S. Cook (Age 56)
    Chairman, Pres & CEO
    Comp: $360k
  • Ms. Donna Medina
    Interim Chief Financial Officer

Key Competitors

View All Competitors













LBL Stock - Frequently Asked Questions

How have LBL shares performed in 2023?

Lattice Biologics' stock was trading at C$0.04 on January 1st, 2023. Since then, LBL shares have increased by 0.0% and is now trading at C$0.04.
View the best growth stocks for 2023 here.

What other stocks do shareholders of Lattice Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lattice Biologics investors own include Cross Timbers Royalty Trust (CRT), 50904 (GRC.V) (GRC), InfraCap MLP ETF (AMZA), Alliance Resource Partners (ARLP), Brigham Minerals (MNRL), Sorrento Therapeutics (SRNE), Arbor Realty Trust (ABR), Advanced Emissions Solutions (ADES) and Archer-Daniels-Midland (ADM).

What is Lattice Biologics' stock symbol?

Lattice Biologics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "LBL."

How do I buy shares of Lattice Biologics?

Shares of LBL stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Lattice Biologics' stock price today?

One share of LBL stock can currently be purchased for approximately C$0.04.

How much money does Lattice Biologics make?

Lattice Biologics (CVE:LBL) has a market capitalization of C$5.13 million and generates C$1.56 million in revenue each year.

How can I contact Lattice Biologics?

Lattice Biologics' mailing address is 16701 N 90th St Ste 101, SCOTTSDALE, AZ 85260-1012, United States. The official website for the company is www.latticebiologics.com. The company can be reached via phone at +1-604-2356701.

This page (CVE:LBL) was last updated on 3/21/2023 by MarketBeat.com Staff